Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Coexpression of c-Jun in multiple-chain DAP-CAR-engineered T-cells for solid tumor therapy.

Immunotherapy - 1 Dec 2022

Xu Tongpeng, Wang Chen, Chen Xiaomei, Bai Jian, Wang Enxiu, Sun Ming

Abstract excerpt

Aim: This work was designed to explore whether c-Jun overexpression could improve the persistence and antitumor efficacy of DAP chimeric antigen receptor T-cell (CAR-T) cells. Methods: The in vitro and in vivo antitumor effects of mesothelin (MSLN) targeting DAP-CAR-T cells were verified by ELISA, real-time cell analysis and in a xenograft model. Results: c-Jun overexpression did not affect DAP-CAR-T...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Immunotherapy, Adoptive
Share to Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Receptors, Chimeric Antigen

Share to T-Lymphocytes

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 36597720
DOI: 10.2217/imt-2022-0171

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Coexpression of c-Jun in multiple-chain DAP-CAR-engineered T-cells for solid tumor therapy.PMID 36597720Read ↗

Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potencySemantic proximity Read ↗

Enhanced Solid Tumor Recognition and T cell Stemness with SynNotch CAR CircuitsSemantic proximity Read ↗

Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.Semantic proximity Read ↗

Balancing activation and co-stimulation of CAR tunes signaling dynamics and enhances therapeutic potencySemantic proximity Read ↗

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myelomaSemantic proximity Read ↗

The expanded application of CAR-T cell therapy for the treatment of multiple non-tumoral diseasesSemantic proximity Read ↗

Chimeric Antigen Receptor T Cells Engineered to Secrete CD40 Agonist Antibodies Enhance Antitumor EfficacySemantic proximity Read ↗

PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.Semantic proximity Read ↗

Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells.Semantic proximity Read ↗

CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.